BioMarin Pharmaceutical Inc. (BMRN) Stock: Price, Forecast & Analyst Target
BioMarin Pharmaceutical Inc. (BMRN) — MoonshotScore 65/100 (Strong band), calculated Oct 4, 2026. Price $57.18 (-2.16%), as of the Oct 2, 2026 trading session; market cap $11.1B. Expected results Oct 26, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 12.70× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Oct 26, 2026
BioMarin Pharmaceutical Inc. · BMRN · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: BioMarin sells treatments for severe rare genetic and metabolic disorders, with an established commercial portfolio rather than a business resting mainly on clinical milestones. The case depends on whether newer portfolio additions and patient growth can lift revenue while earnings, operating expenses and liquidity settle into a more durable pattern.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · BioMarin Pharmaceutical (BMRN)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Growing; Momentum: Rising.
- quarterly revenue $990M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 5 of 8
- Altman Z 1.86 · Piotroski F 4
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 65 | Strong | |
| 65 | Strong | |
| 65 | Fair | |
| 65 | Fair | |
| 65 | Strong | |
| 65 | Strong |
The score was 65 in the stored Oct 3, 2026 snapshot and remains 65 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Financial Safety +1 and Growth Durability -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $57.18 |
| Change on the day | -2.16% |
| 52-week range | $49.26–$70.98 |
| Market capitalisation | $11.1B |
| Price / earnings (trailing) | 150.47 |
| Shares traded on the day | 2.19M |
| Beta (volatility vs the S&P 500) | 0.24 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
First quarter non-GAAP diluted earnings per share was $0.76 and was significantly impacted by the drivers of increased operating expense that I just mentioned, as well as the impact of Q1 revenue which we believe will be our lowest quarter of the year.
Brian Mueller · Statement from
To give some perspective on timing of the updated guidance, we expect order timing for the historical BioMarin Pharmaceutical Inc. products and two full quarters of Galafold and Pombility and Opfolda revenues in the second half of the year to drive significantly higher revenues as compared to the first half of 2026.
Brian Mueller · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for BioMarin Pharmaceutical (BMRN): Bullish Lean
67/100 · B+Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the BMRN film — every key number, told as a short cinematic story
~2 min · open the film
What is BioMarin Pharmaceutical (BMRN), and what does it report?
Short answer · as of
BioMarin earns nearly all of its revenue from medicines such as Vimizim, Naglazyme, Palynziq, Brineura and Voxzogo; royalties and other revenue are peripheral.
Research dated 2026-09-13.
BioMarin earns nearly all of its revenue from medicines such as Vimizim, Naglazyme, Palynziq, Brineura and Voxzogo; royalties and other revenue are peripheral. Demand reflects diagnosed and treated patients, new therapy starts, dose progression and purchasing schedules across specialty pharmacies, hospitals, government health bodies, distributors and wholesalers.
That commercial base makes BioMarin different from a clinical-stage biotechnology company whose value depends chiefly on trial outcomes. Research remains substantial, but the reported income statement already measures a global rare-disease franchise with meaningful product sales and positive annual earnings.
What do the latest results show for BioMarin Pharmaceutical (BMRN)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $990M.
Research dated 2026-09-13.
The latest period delivered the strongest revenue in the reported quarterly series, positive operating and net income, and revenue and earnings above market expectations. Profit did not rise with sales, however: operating income and net income declined from the preceding period as research and administrative spending increased.
Management had previously expected purchasing schedules and fuller contributions from Galafold, Pombility and Opfolda to make the later part of the year stronger than the earlier part. That explanation identifies the commercial mechanism, but the expense pattern shows why revenue growth alone does not establish durable earnings growth.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $989.71M Jun 30, 2026
- Latest quarter · R&D
- $206.95M Jun 30, 2026
- Latest quarter · SG&A
- $395.54M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $110.93M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $989.71M | $206.95M | $395.54M | $110.93M |
| Mar 31, 2026 | $766.21M | $178.80M | $258.30M | $129.63M |
| Dec 31, 2025 | $874.57M | $192.41M | $802.12M | $79.39M |
| Sep 30, 2025 | $776.13M | $409.48M | $268.42M | −$46.69M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $989.71M Aug 6, 2026
- Latest report · revenue estimate
- $932.03M Aug 6, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 6, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 6, 2026 | $989.71M | $932.03M | $1.2000 | $0.9470 |
| May 4, 2026 | $766.00M | $752.53M | $0.7600 | $0.7800 |
| Feb 23, 2026 | $874.57M | $833.73M | −$0.2400 | $0.1694 |
| Oct 27, 2025 | $776.13M | $777.48M | −$0.1600 | −$0.1500 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $990M | $45M | $0.23 (diluted) |
| Q1 FY2026 | $766M | $106M | $0.54 (diluted) |
| Q4 FY2025 | $875M | -$47M | -$0.22 (diluted) |
| Q3 FY2025 | $776M | -$31M | -$0.16 (diluted) |
What are the financial strengths and risks for BioMarin Pharmaceutical (BMRN)?
Short answer
Cash and short-term investments were $874.01M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $168.11M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operations have generated cash throughout the reported quarterly window, while capital spending has remained modest relative to operating inflows. High gross profitability also gives BioMarin room to fund research and commercialization, although recent swings in operating and net margins show that this room can be consumed quickly.
Debt substantially exceeds cash and investments, and the latest cash balance fell sharply from the preceding period. Near-term liquidity ratios remain supportive, but cash alone would cover only a limited portion of total debt; the broader quality and distress screens therefore sit alongside genuine cash generation rather than replacing scrutiny of leverage.
The business-specific financial risk is that patient starts, titration or order timing disappoint while research and commercial costs remain elevated. Because revenue is overwhelmingly product based, disruption across the marketed portfolio would reach cash generation more directly than weakness in the small royalty stream.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $168.11M Jun 30, 2026
- Previous quarter · operating cash flow
- $220.65M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $168.11M | −$28.82M |
| Mar 31, 2026 | $220.65M | −$20.92M |
| Dec 31, 2025 | $99.64M | −$40.72M |
| Sep 30, 2025 | $368.69M | −$33.75M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at BioMarin Pharmaceutical (BMRN)?
Short answer · as of
The next earnings report is expected on Oct 26, 2026.
Research dated 2026-09-13.
Watch whether Galafold, Pombility and Opfolda provide the fuller contribution management anticipated, whether enzyme therapies sustain growth, and whether Palynziq gains from new patient starts and progression toward maintenance dosing. These observations test management's stated revenue mechanism rather than merely comparing the result with consensus.
The accompanying financial checks are whether operating profit keeps pace with revenue, operating cash flow remains positive and the cash balance stabilizes after its recent drop. Longer-range market estimates assume continued expansion in revenue and earnings, so recurring expense volatility or weak cash conversion would make that path harder to support.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
First quarter non-GAAP diluted earnings per share was $0.76 and was significantly impacted by the drivers of increased operating expense that I just mentioned, as well as the impact of Q1 revenue which we believe will be our lowest quarter of the year.
Brian Mueller ·
To give some perspective on timing of the updated guidance, we expect order timing for the historical BioMarin Pharmaceutical Inc. products and two full quarters of Galafold and Pombility and Opfolda revenues in the second half of the year to drive significantly higher revenues as compared to the first half of 2026.
Brian Mueller ·
With Cristin, who will discuss in more detail, we expect Enzyme Therapies will deliver robust growth in 2026, further supported by the addition of Galafold and Pombility and Opfolda to the portfolio.
Alexander Hardy ·
We expect this stocking dynamic to normalize and anticipate year-over-year revenue growth for Palynziq in full year 2026 as growth in new patient starts in the 12 to 18-year-old population gains momentum and patients continue to titrate to their maintenance dose.
Brian Mueller ·
How does BioMarin Pharmaceutical compare with its peers?
Short answer
BioMarin Pharmaceutical's score ranks tied for 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
BioMarin sits between a development-stage biotechnology company and a broad pharmaceutical manufacturer. It has multiple marketed rare-disease therapies, specialized distribution channels and substantial product revenue, yet its portfolio remains concentrated in small patient populations where diagnosis, treatment initiation, titration and purchasing schedules can materially affect sales timing.
Compared with pipeline-led peers, existing products provide revenue, gross profit and operating cash flow that can finance development work. Compared with diversified drugmakers, BioMarin retains greater exposure to individual rare-disease franchises and to the research and commercialization demands surrounding them.
| Company | Price | Market value | Score |
|---|---|---|---|
| $58.39 Oct 2, 2026 | $14.7B | 98 5-pillar Oct 4, 2026 | |
| $322.28 Oct 2, 2026 | $9.54B | 97 5-pillar Oct 4, 2026 | |
| $72.40 Oct 2, 2026 | $11.3B | 93 5-pillar Oct 4, 2026 | |
| $116.23 Oct 2, 2026 | $12.6B | 91 5-pillar Oct 4, 2026 | |
| $143.18 Oct 2, 2026 | $14.4B | 90 5-pillar Oct 4, 2026 | |
| $28.30 Oct 2, 2026 | $8.00B | 89 5-pillar Oct 4, 2026 | |
| $109.86 Oct 2, 2026 | $13.0B | 88 5-pillar Oct 4, 2026 | |
| $227.87 Oct 2, 2026 | $14.2B | 88 5-pillar Oct 4, 2026 | |
| $143.74 Oct 2, 2026 | $10.3B | 83 5-pillar Oct 4, 2026 | |
| $140.06 Oct 2, 2026 | $9.01B | 76 5-pillar Oct 4, 2026 | |
| BioMarin Pharmaceutical (BMRN) — this page | $57.18 | $11.1B | 65 |
| $54.29 Oct 2, 2026 | $8.31B | 65 5-pillar Oct 4, 2026 | |
| $41.75 Oct 2, 2026 | $7.00B | 64 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $59.00 – $124.00
- Consensus target
- $90.88
- Median target
- $90.00
Consensus record · Captured .
Measured against a quoted price of $57.18 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 14
- Identified insiders
- 13
- Purchases
- 0
- Sales
- 2
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 587 Period end Jun 30, 2026
- Previous quarter · holders
- 585 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 20,445,212 |
| Dodge & Cox | 14,844,930 |
| Primecap Management Co/Ca/ | 14,190,183 |
| Vanguard Capital Management LLC | 8,743,633 |
| Vanguard Portfolio Management LLC | 8,648,678 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about BioMarin Pharmaceutical (BMRN)?
- BioMarin Says 5-Year Data Shows Durable Efficacy of Pombiliti Plus Opfolda in Pompe Disease
- BioMarin Pharmaceutical Presents New Efficacy Data On POMBILITI + OPFOLDA In Pompe Disease At 31st Annual Congress Of World Muscle Society; No New Safety Signals Identified
- BioMarin reports five-year Pompe disease data showing durable motor function
- BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
What Investors Ask About BioMarin Pharmaceutical (BMRN) — Healthcare
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Galafold, Pombility and Opfolda change BioMarin's commercial profile?
They broaden the enzyme-therapy portfolio beyond BioMarin's historical products. Management expected fuller contributions from these medicines to support stronger later-period revenue, making their commercial uptake important to the growth narrative.
Why can Palynziq sales move differently from patient starts?
Purchasing and stocking can shift revenue between reporting periods, while newly treated patients must progress toward maintenance dosing. Patient growth may therefore precede its full effect on reported sales.
What makes Voxzogo different from BioMarin's enzyme therapies?
Voxzogo is a daily injectable therapy for achondroplasia, whereas products such as Vimizim and Naglazyme replace enzymes for specific metabolic disorders. They share specialized rare-disease channels but address different conditions through different treatment mechanisms.
Does BioMarin rely mainly on its gene-therapy pipeline?
Marketed medicines already produce nearly all company revenue, so the business is not chiefly dependent on pipeline assets for current sales. Gene-therapy programs add development potential alongside an established commercial portfolio.
What is the BMRN stock price today?
The last price recorded on this page for BioMarin Pharmaceutical Inc. (BMRN) is $57.18, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BMRN price target?
The analyst consensus price target for BioMarin Pharmaceutical Inc. (BMRN) is $90.88 (range $59.00 to $124.00, median $90.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (81 figures)
The 81 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Brian Mueller (May 4, 2026): First quarter non-GAAP diluted earnings per share was $0.76 and was significantly impacted by the drivers of increased operating expense that I just mentioned, as well as the impact of Q1 revenue which we believe will be our lowest quarter of the year. Brian Mueller (May 4, 2026): To give some perspective on timing of the updated guidance, we expect order timing for the historical BioMarin Pharmaceutical Inc. products and two full quarters of Galafold and Pombility and Opfolda revenues in the second half of the year to drive significantly higher revenues as compared to the first half of 2026. Alexander Hardy (May 4, 2026): With Cristin, who will discuss in more detail, we expect Enzyme Therapies will deliver robust growth in 2026, further supported by the addition of Galafold and Pombility and Opfolda to the portfolio. Brian Mueller (May 4, 2026): We expect this stocking dynamic to normalize and anticipate year-over-year revenue growth for Palynziq in full year 2026 as growth in new patient starts in the 12 to 18-year-old population gains momentum and patients continue to titrate to their maintenance dose. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Novato, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "770 Lindaro Street, San Rafael, CA, 94901, US". The FMP company description names San Rafael, California as the headquarters; this page uses the address in this row. |
FMP — 72 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 26, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $57.18 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:40.633Z. | |
px.change | Change on the day | -2.16% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $11.1B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T20:54:39.019Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$1.26 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $990M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $49.26–$70.98 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 150.47 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.19M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.24 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Alexander Hardy | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 3,221 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $1.85B, net result −$64.08M; FY2022 revenue $2.10B, net result $141.56M; FY2023 revenue $2.42B, net result $167.65M; FY2024 revenue $2.85B, net result $426.86M; FY2025 revenue $3.22B, net result $348.90M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Product $3.17B · Royalty And Other $53.49M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 51.0% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $989.71M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $206.95M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $395.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $110.93M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $766.21M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $178.80M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $258.30M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $129.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $874.57M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $192.41M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $802.12M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $79.39M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $776.13M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $409.48M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $268.42M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$46.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-06.revenue_actual | Revenue · reported — report date 2026-08-06 | $989.71M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.revenue_estimated | Revenue · estimate — report date 2026-08-06 | $932.03M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_actual | EPS · reported — report date 2026-08-06 | $1.2000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_estimated | EPS · estimate — report date 2026-08-06 | $0.9470 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.revenue_actual | Revenue · reported — report date 2026-05-04 | $766.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.revenue_estimated | Revenue · estimate — report date 2026-05-04 | $752.53M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.eps_actual | EPS · reported — report date 2026-05-04 | $0.7600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-04.eps_estimated | EPS · estimate — report date 2026-05-04 | $0.7800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.revenue_actual | Revenue · reported — report date 2026-02-23 | $874.57M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.revenue_estimated | Revenue · estimate — report date 2026-02-23 | $833.73M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.eps_actual | EPS · reported — report date 2026-02-23 | −$0.2400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.eps_estimated | EPS · estimate — report date 2026-02-23 | $0.1694 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.revenue_actual | Revenue · reported — report date 2025-10-27 | $776.13M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.revenue_estimated | Revenue · estimate — report date 2025-10-27 | $777.48M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.eps_actual | EPS · reported — report date 2025-10-27 | −$0.1600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.eps_estimated | EPS · estimate — report date 2025-10-27 | −$0.1500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $874.01M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $168.11M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $9.46M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $4.20B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 1.75× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $168.11M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $220.65M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$28.82M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$20.92M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $99.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$40.72M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $368.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$33.75M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $59.00 – $124.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $90.88 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $90.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 14 transactions · 0 purchases, 2 sales, 12 other transactions · 13 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 30, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 587 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 585 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 20,445,212 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Dodge & Cox — shares in provider snapshot | 14,844,930 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Primecap Management Co/Ca/ — shares in provider snapshot | 14,190,183 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Capital Management LLC — shares in provider snapshot | 8,743,633 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 8,648,678 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 1.86 · Piotroski F 4 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 12.70× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $874.01M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-06.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($989.71M) with the recorded estimate ($932.03M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-06.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.2000) with the recorded estimate ($0.9470) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 65 of 100 · Strong · pillars 80 / 23 / 62 / 64 / 68 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 65 (stored snapshot Oct 3, 2026) → 65 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-06. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-06.revenue_actual,earn.history.depth.2026-08-06.revenue_estimated,earn.history.depth.2026-08-06.revenue_actual.comparison,earn.history.depth.2026-08-06.eps_actual.comparison,earn.history.depth.2026-08-06.eps_actual,earn.history.depth.2026-08-06.eps_estimated,earn.history.depth.2026-05-04.revenue_actual,earn.history.depth.2026-05-04.revenue_estimated,earn.history.depth.2026-05-04.eps_actual,earn.history.depth.2026-05-04.eps_estimated,earn.history.depth.2026-02-23.revenue_actual,earn.history.depth.2026-02-23.revenue_estimated,earn.history.depth.2026-02-23.eps_actual,earn.history.depth.2026-02-23.eps_estimated,earn.history.depth.2025-10-27.revenue_actual,earn.history.depth.2025-10-27.revenue_estimated,earn.history.depth.2025-10-27.eps_actual,earn.history.depth.2025-10-27.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Product: $3.17B; Royalty And Other: $53.49M | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-05-04 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-06 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-08-06 | OFFICIAL | SEC EDGAR filer submissions | |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Trailing twelve-month ratio set | Quick ratio: 1.32; Current ratio: 2.39; Debt to equity: 0.66; Net margin: 2.1%; Gross margin: 75.5%; Operating margin: 8%; Return on assets: 0.6%; Return on equity: 1.2% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Cash, investments and debt | Total debt: $4.20B; Liquidity basis: cash and short-term investments; Total liabilities: $5.40B; Cash and short-term investments: $874.01M; Cash and investments: $883.50M; Long-term investments: $9.46M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $883.50M; Cash and short-term investments: $874.00M; Long-term investments: $9.50M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$3.33B; Total debt: $4.20B; Cash and investments: $874.00M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Distress and quality screens | Altman Z-score: 2.04; Piotroski F-score: 4 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2026-10-26; EPS estimate: $1.35 per share; Revenue estimate: $1.03B The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Recent SEC filings |
| 2026-09-01 | OFFICIAL | SEC EDGAR filer submissions |
Data provided for informational purposes only.
ETFs that hold BMRN
Funds in our ETF coverage that list BMRN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Global X - Genomics & Biotechnology ETF (GNOM) | 4.31% | |
| Alger Russell Innovation ETF (INVN) | 2.52% |